Skip to content

Lobbying by Novartis Pharmaceuticals Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

Novartis Pharmaceuticals Canada Inc.

Meetings this Parliament
36
With MPs
15
Since Nov 2021
93
Active registrations
1

Most recent reported meeting: Sep 23, 2026.

Who they meet

Since the current Parliament opened.

MPs

Institutions

  • House of Commons12
  • Health Canada (HC)11
  • Innovation, Science and Economic Development Canada (ISED)8
  • Finance Canada (FIN)3
  • Prime Minister's Office (PMO)2
  • Privy Council Office (PCO)1
  • Natural Resources Canada (NRCan)1
  • Intergovernmental Affairs Secretariat (IGA)1

Registrations in effect

In-house (corporation) In effect since May 19, 2026

Filed by Dimitri Gitas, Country President

Lobbyists

  • Guillaume Demers · Director - Public Affairs
  • Shona Kinley · Vice-President Public Affairs Former public office holder

    Formerly Special Assistant, Minister's Office, Health Canada (1996–1996)

Institutions they may lobby: Atlantic Canada Opportunities Agency (ACOA), Canadian Heritage (PCH), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Natural Resources Canada (NRCan), Pacific Economic Development Canada (PacifiCan), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)

What they're lobbying on (9)
  • The CUSMA renegotiation and issues related to the pharmaceutical industry in Canada.
  • Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, as well as the Intellectual Property performance review, as noted in budget 2026.
  • Free trade agreements as they relate to biomanufacturing industry in Canada. Engage, as a stakeholder, to provide input into the re-negotiation of the Canada USA Mexico trade agreement "CUSMA"
  • Patented Medicines Regulations modernization as outlined in Budget 2026, that will leverage existing technology, enabling faster and more cost effective procedural processes.
  • Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
  • R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB)
  • Patented Medicine Prices Review Board (PMPRB) Regulations as related to reporting requirements and pricing guidelines.
  • Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries
  • Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.

Registration 962869-15599-43. Look it up in the official Registry

Reported meetings

Spreadsheet

Filed by Mark Vineis (35), Dimitri Gitas (21), Andrea Marazzi (17), Christian Macher (14), Pedro Ferreira (6).

  • Reported by Dimitri Gitas · In-house (corporation)

    • Anson Duran · Chief of Staff, Innovation, Science and Economic Development Canada (ISED)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, as well as the Intellectual Property performance review, as noted in budget 2026. Read more

    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    • Mélanie Joly · Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    • Mark Carney · Prime Minister of Canada, Prime Minister's Office (PMO)
    • Marc-André Blanchard · Chief of Staff, Prime Minister's Office (PMO)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    • Niloo Boroun · Director of International Policy, Finance Canada (FIN)
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    The CUSMA renegotiation and issues related to the pharmaceutical industry in Canada. Read more

    Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, as well as the Intellectual Property performance review, as noted in budget 2026.

    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    • Galen Richardson · Senior Advisor, Stakeholder Relations, Privy Council Office (PCO)
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada. Read more

    Free trade agreements as they relate to biomanufacturing industry in Canada. Engage, as a stakeholder, to provide input into the re-negotiation of the Canada USA Mexico trade agreement "CUSMA"

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada. Read more

    Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, as well as the Intellectual Property performance review, as noted in budget 2026.

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    • Matthew Trnkus · Senior Policy Advisor, Global Affairs Canada (GAC)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada. Read more

    Free trade agreements as they relate to biomanufacturing industry in Canada. Engage, as a stakeholder, to provide input into the re-negotiation of the Canada USA Mexico trade agreement "CUSMA"

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    • Jade Mallette · Chief of Staff to the Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    • Paul Moen · Chief of Staff to the Minister, Innovation, Science and Economic Development Canada (ISED)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    • Marjorie Michel · Minister of Health
    • Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    • Marjorie Michel · Minister of Health, Health Canada (HC)
    • Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
    • Mahamat Djalal · Policy Advisor, Health Canada (HC)
    • Alexandre Bergeron · Press Secretary, Health Canada (HC)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    • Tom Kmiec · Member of Parliament, Calgary Shephard
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    • Jibril Hussein · Intern, Innovation, Science and Economic Development Canada (ISED)
    • Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
    Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Dimitri Gitas · In-house (corporation)

    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Mark Vineis · In-house (corporation)

    • Mahamat Djalal · Director of Policy, Quebec, Health Canada (HC)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Mark Vineis · In-house (corporation)

    • Shawn Boyle · Chief of Staff, House of Commons
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Mark Vineis · In-house (corporation)

    • Marie-Christine Demers · Senior Policy Advisor, Natural Resources Canada (NRCan)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Reported by Mark Vineis · In-house (corporation)

    Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more

    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.